Literature DB >> 22562936

The expression of APRIL in Sjogren's syndrome: aberrant expression of APRIL in the salivary gland.

Jelle L Vosters1, Nienke Roescher, Eline J Polling, Gabor G Illei, Paul P Tak.   

Abstract

OBJECTIVE: A proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF) are B-cell-related mediators and may play a role in the pathogenesis in SS. In this descriptive study we assessed the expression of APRIL and BAFF in the minor salivary gland and serum from SS patients.
METHODS: Paraffin-embedded minor salivary gland sections from SS patients, non-SS controls and healthy volunteers were analysed by immunohistochemistry. Digital image quantification was performed to evaluate the expression of BAFF, APRIL and transmembrane activator and CAML interactor. Furthermore, serum was analysed for soluble BAFF and APRIL levels by ELISA. All the data were also analysed for subjects with decreased and normal stimulated salivary flow independent of the classification.
RESULTS: APRIL expression was lower in minor salivary gland biopsies from SS patients compared with healthy volunteers and to a lesser extent non-SS controls, whereas BAFF expression was similar in all groups. Soluble APRIL levels in serum were increased in SS patients and in subjects with decreased salivary flow independent of the classification.
CONCLUSION: APRIL salivary gland tissue levels are decreased, suggesting that targeting this cytokine locally in the salivary glands would not benefit SS patients. Moreover, the discrepancy between local and systemic levels is striking and future research should assess this in more detail.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562936      PMCID: PMC3418645          DOI: 10.1093/rheumatology/kes080

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  20 in total

Review 1.  B-cell targeted therapies in human autoimmune diseases: an updated perspective.

Authors:  Michael J Townsend; John G Monroe; Andrew C Chan
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

2.  Absence of up-regulation for a proliferation-inducing ligand in Sjögren's sialadenitis lesions.

Authors:  Tommaso Lombardi; Solange Moll; Pierre Youinou; Jacques-Olivier Pers; Alexander Tzankov; Cem Gabay; Marie-Laure Santiago-Raber; Carlo Chizzolini; Bertrand Huard
Journal:  Rheumatology (Oxford)       Date:  2011-02-16       Impact factor: 7.580

3.  Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjögren's syndrome.

Authors:  Shizuka Tsunawaki; Seiji Nakamura; Yukiko Ohyama; Masanori Sasaki; Akiko Ikebe-Hiroki; Akimitsu Hiraki; Tsutomu Kadena; Eui Kawamura; Wataru Kumamaru; Masanori Shinohara; Kanemitsu Shirasuna
Journal:  J Rheumatol       Date:  2002-09       Impact factor: 4.666

4.  Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome.

Authors:  Arne Hansen; Marcus Odendahl; Karin Reiter; Annett M Jacobi; Eugen Feist; Jürgen Scholze; Gerd R Burmester; Peter E Lipsky; Thomas Dörner
Journal:  Arthritis Rheum       Date:  2002-08

5.  Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.

Authors:  J Morel; C Roubille; L Planelles; C Rocha; L Fernandez; C Lukas; M Hahne; B Combe
Journal:  Ann Rheum Dis       Date:  2008-08-02       Impact factor: 19.103

6.  Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways.

Authors:  Marc Ittah; Corinne Miceli-Richard; Jacques-Eric Gottenberg; Jérémie Sellam; Pierre Eid; Pierre Lebon; Coralie Pallier; Christine Lepajolec; Xavier Mariette
Journal:  Eur J Immunol       Date:  2008-04       Impact factor: 5.532

7.  Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development.

Authors:  Vassilia-Ismini Alexaki; George Notas; Vassiliki Pelekanou; Marilena Kampa; Maria Valkanou; Panayiotis Theodoropoulos; Efstathios N Stathopoulos; Andreas Tsapis; Elias Castanas
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

8.  BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands.

Authors:  Ghada Alsaleh; Laurent Messer; Noha Semaan; Nathalie Boulanger; Jacques-Eric Gottenberg; Jean Sibilia; Dominique Wachsmann
Journal:  Arthritis Rheum       Date:  2007-10

Review 9.  An APRIL to remember: novel TNF ligands as therapeutic targets.

Authors:  Stacey R Dillon; Jane A Gross; Stephen M Ansell; Anne J Novak
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

10.  B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.

Authors:  Marc Ittah; Corinne Miceli-Richard; Jacques- Eric Gottenberg; Frédéric Lavie; Thierry Lazure; Nathalie Ba; Jérémie Sellam; Christine Lepajolec; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2006-02-28       Impact factor: 5.156

View more
  3 in total

1.  Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept.

Authors:  N Roescher; J L Vosters; G Alsaleh; P Dreyfus; S Jacques; G Chiocchia; J Sibilia; P P Tak; J A Chiorini; X Mariette; Jacques-Eric Gottenberg
Journal:  Mol Ther       Date:  2013-12-05       Impact factor: 11.454

2.  APRIL gene polymorphism and serum sAPRIL levels in children with systemic lupus erythematosus.

Authors:  Shideh Namazi; Nader Tajik; Vahid Ziaee; Maryam Sadr; Samaneh Soltani; Arezou Rezaei; Samaneh Zoghi; Nima Rezaei
Journal:  Clin Rheumatol       Date:  2016-11-23       Impact factor: 2.980

3.  Subgroups of Sjögren's syndrome patients categorised by serological profiles: clinical and immunological characteristics.

Authors:  Ewa Kontny; Aleksandra Lewandowska-Poluch; Magdalena Chmielińska; Marzena Olesińska
Journal:  Reumatologia       Date:  2018-12-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.